Advanced search
Publication Cover
Expert Opinion on Pharmacotherapy Volume 18, 2017 - Issue 13
Submit an article Journal homepage
972
Views
26
CrossRef citations to date
0
Altmetric
Drug Evaluation

The safety and efficacy of the 5-HT 1F receptor agonist lasmiditan in the acute treatment of migraine

Bianca RaffaelliDepartment of Neurology, Charité Universitätsmedizin Berlin, Berlin, GermanyView further author information
,
Heike IsraelDepartment of Neurology, Charité Universitätsmedizin Berlin, Berlin, GermanyView further author information
,
Lars NeebDepartment of Neurology, Charité Universitätsmedizin Berlin, Berlin, GermanyView further author information
&
Uwe ReuterDepartment of Neurology, Charité Universitätsmedizin Berlin, Berlin, GermanyCorrespondence[email protected]
View further author information
Pages 1409-1415 | Received 17 May 2017, Accepted 21 Jul 2017, Published online: 10 Aug 2017

Citations (26)

Keep up to date with the latest research on this topic with citation updates for this article.

Subscribe to citation updates

Read on this site (3)

Wade Cooper, Erin Gautier Doty, Helen Hochstetler, Ann Hake & Vincent Martin. (2020) The current state of acute treatment for migraine in adults in the United States. Postgraduate Medicine 132:7, pages 581-589.
Read now
Eleonora De Matteis, Martina Guglielmetti, Raffaele Ornello, Valerio Spuntarelli, Paolo Martelletti & Simona Sacco. (2020) Targeting CGRP for migraine treatment: mechanisms, antibodies, small molecules, perspectives. Expert Review of Neurotherapeutics 20:6, pages 627-641.
Read now
Jessica C Oswald & Nathaniel M Schuster. (2018) Lasmiditan for the treatment of acute migraine: a review and potential role in clinical practice. Journal of Pain Research 11, pages 2221-2227.
Read now

Articles from other publishers (23)

Rituparna Maiti, Archana Mishra, Haridas Mundot Puliappadamb, Monalisa Jena & Anand Srinivasan. (2021) Efficacy and Safety of Lasmiditan for Acute Treatment of Migraine in Adults: A Meta‐Analysis. The Journal of Clinical Pharmacology 61:12, pages 1534-1544.
Crossref
Paul A DeJulio, Joshua K Perese, Nathaniel M Schuster & Jessica C Oswald. (2021) Lasmiditan for the acute treatment of migraine. Pain Management 11:5, pages 437-449.
Crossref
Xinna Wang, Hongfei Zhao, Liming Liu, Ping Niu, Chao Zhai, Jinjian Li, Qiaoli Xu & Dexi Zhao. (2020) Hejie Zhitong prescription promotes sleep and inhibits nociceptive transmission-associated neurotransmitter activity in a rodent migraine model. Chinese Medicine 15:1.
Crossref
Min Hou, Haiyan Xing, Chen Li, Xianfeng Wang, Dongmei Deng, Juan Li, Pan Zhang & Jianhong Chen. (2020) Short-term efficacy and safety of lasmiditan, a novel 5-HT1F receptor agonist, for the acute treatment of migraine: a systematic review and meta-analysis. The Journal of Headache and Pain 21:1.
Crossref
David B. Clemow, Kirk W. Johnson, Helen M. Hochstetler, Michael H. Ossipov, Ann M. Hake & Andrew M. Blumenfeld. (2020) Lasmiditan mechanism of action – review of a selective 5-HT1F agonist. The Journal of Headache and Pain 21:1.
Crossref
Spingos Konstantinos, Michail Vikelis & Alan Rapoport. (2020) Acute Care and Treatment of Migraine. Journal of Neuro-Ophthalmology 40:4, pages 472-484.
Crossref
Hui Zhu, Yongguo Tang, Ting Zhou & Jing Song. (2020) The Efficacy of Lasmiditan for the Treatment of Migraine: A Meta-Analysis of Randomized Controlled Studies. Clinical Neuropharmacology 43:6, pages 191-195.
Crossref
Yanbo Yang, Yue Sun, Bixi Gao, Zilan Wang, Zhouqing Chen & Zhong Wang. (2020) Lasmiditan for Acute Treatment of Migraine in Adults: A Systematic Review and Meta-analysis of Randomized Controlled Trials. CNS Drugs 34:10, pages 1015-1024.
Crossref
G. R. Tabeeva & Z. Katsapava. (2020) Current concept of the pathophysiology of migraine and new targets for its therapy. Neurology, Neuropsychiatry, Psychosomatics 12:4, pages 143-152.
Crossref
Tessa de Vries, Carlos M. Villalón & Antoinette MaassenVanDenBrink. (2020) Pharmacological treatment of migraine: CGRP and 5-HT beyond the triptans. Pharmacology & Therapeutics 211, pages 107528.
Crossref
Max Tsai, Michael Case, Paul Ardayfio, Helen Hochstetler & Darren Wilbraham. (2020) Effects of Lasmiditan on Cardiovascular Parameters and Pharmacokinetics in Healthy Subjects Receiving Oral Doses of Propranolol. Clinical Pharmacology in Drug Development 9:5, pages 629-638.
Crossref
Heui-Soo Moon, Kwang-Yeol Park, Jae-Myun Chung & Byung-Kun Kim. (2020) An Update On Migraine Treatment. Journal of the Korean Neurological Association 38:2, pages 100-110.
Crossref
Hong-Kyun Park & Byung-Kun Kim. (2020) Calcitonin Gene-Related Peptide Targeting Therapies for Migraine: A New Era for Migraine Treatment. Journal of the Korean Neurological Association 38:2, pages 88-99.
Crossref
. 2020. Diagnostik und Therapie neurologischer Erkrankungen. Diagnostik und Therapie neurologischer Erkrankungen 353 420 .
Peter J Goadsby, Linda A Wietecha, Ellen B Dennehy, Bernice Kuca, Michael G Case, Sheena K Aurora & Charly Gaul. (2019) Phase 3 randomized, placebo-controlled, double-blind study of lasmiditan for acute treatment of migraine. Brain 142:7, pages 1894-1904.
Crossref
Richard Hargreaves & Jes Olesen. (2019) Calcitonin Gene‐Related Peptide Modulators – The History and Renaissance of a New Migraine Drug Class. Headache: The Journal of Head and Face Pain 59:6, pages 951-970.
Crossref
Katharina Kamm, Andreas Straube & Lars Neeb. (2019) Migräne — Therapie im WandelMigraine — therapy in transition. MMW - Fortschritte der Medizin 161:12, pages 50-58.
Crossref
Daniel Martins. 2019. The Serotonin System. The Serotonin System 203 224 .
. (2018) The American Headache Society Position Statement On Integrating New Migraine Treatments Into Clinical Practice. Headache: The Journal of Head and Face Pain.
Crossref
Shazia K Afridi. (2018) Current concepts in migraine and their relevance to pregnancy. Obstetric Medicine 11:4, pages 154-159.
Crossref
Robert P. Cowan. (2018) The Future of Migraine Prevention. Headache: The Journal of Head and Face Pain 58, pages 291-297.
Crossref
Lars Edvinsson, Kristian Agmund Haanes, Karin Warfvinge & Diana N. Krause. (2018) CGRP as the target of new migraine therapies — successful translation from bench to clinic. Nature Reviews Neurology 14:6, pages 338-350.
Crossref
Marta Vila-Pueyo. (2018) Targeted 5-HT1F Therapies for Migraine. Neurotherapeutics 15:2, pages 291-303.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.